<img height="1" width="1" style="display:none" src="https://q.quora.com/_/ad/1ac644d4c3f54087bef4289a089c9d7c/pixel?tag=ViewContent&amp;noscript=1">

3 Family Offices Investing in Healthcare & Biotechnology

November 24, 2020

As various industries continue to gain traction from family offices, we continue to shine a light on the alternative wealth space by providing detailed analysis regarding the past investment history of these private wealth groups. In utilizing the FINTRX Buy-Side platform, which provides intel into thousands of direct deal transactions made by nearly 3,000 family offices around the world, we have uncovered three family offices investing in the healthcare and biotechnology industries. 


Wasson_Enterprise1. Wasson Enterprise  

Founded in 2016, Wasson Enterprise is a Chicago, IL-based single family office managing the wealth of Gregory Wasson and his family. Wasson accumulated his wealth via an extensive career with Walgreens Company, where he served as CEO from 2009-2014. After retiring, Wasson formed 'Wasson Enterprise' to serve as the family's private investment vehicle. The firm actively seeks to invest in businesses with purposeful missions across a range of industries including healthcare, technology, biotechnology, education, real estate, food and beverage and numerous others. In March of 2017, the firm made a direct investment in Sterilis Solutions, a medical waste remediation company founded in 2011. With headquarters in Boxborough, MA, Sterilis manufactures a ready-access remediation device that turns regulated medical waste (including COVID-19) into harmless, standard waste. In December of 2019, Wasson directly invested in Innovation, a privately-held Pharmacy Automation Technology company headquartered in Johnson City, NY. With over  1,500 systems installed worldwide, its pharmacy automation solutions work nonstop in market segments across the board, from retail chains and independent pharmacies to hospitals and the Department of Defense. Wasson makes majority and minority investments in its portfolio companies and actively co-invests alongside other like-minded family offices. The group takes a firm stance on impact investing and ensures every allocation is socially responsible.

 

2. Massa Investment GroupMassa_Investment_Group

Established in 2009, Massa Investment Group is a Miami, FL-based single family office managing the wealth of its founder, Mathieu Massa. Born in France, Massa inherited much of his wealth from his family who were prominent entrepreneurs in the French wine, real estate, automotive and horse breeding industries. In the early 2000s, Mathieu Massa expanded his family's business interests to the United States, capitalizing on the real estate crisis of 2008. Since its inception, Massa Investment Group has expanded its reach from Florida and the US to include investment opportunities in France. The firm specializes in real estate development and hospitality and targets opportunities across the healthcare, biotechnology, food and beverage industries. For instance, in June of 2019 Massa Investment Group made a direct investment in MODAG, a privately-held German biotech company revolutionizing the field of neurodegenerative disease treatment. With headquarters in Mountain View, CA, MODAG’s approach offers a unique combination of early diagnosis and targeted disease-modifying therapies for severe neurological disorders. 


BPO_Capital_logo

3. BPO Capital

Founded in 2014, BPO Capital is a Hamburg, Germany-based single family office serving as the direct investment arm of its founder Benjamin Otto. As the subsidiary of the Otto Group, BPO Capital places greater emphasis on technology startups and actively seeks to invest in pioneering industries such as blockchain and crowdsourcing. The firm actively seeks to invest in companies that address the trend of the sharing economy. In October of 2018, BPO Capital made a direct investment in Protembis, an Aachen, Germany-based medical device startup established with a vision to reduce the risk of cerebrovascular events, thereby improving outcomes and making TAVR even safer – especially in light of TAVR shifting to younger and lower-risk patients. In December of 2019, BPO Capital made a direct investment in Immunservice GmbH, a Hamburg, Germany-based company developing biological drugs that activate the body's immune system to eliminate cancer and viral infections. With a primary focus on kidney cancer and melanoma, Immunservice develops particularly well-tolerated therapy methods to preserve the quality of life for patients during therapy. BPO Capital is an impact investor and will co-invest alongside other early-stage investors, where applicable. 

Continue exploring complete profiles of nearly 3,000 family offices around the world by leveraging state-of-the-art data exploration and visualization tools designed to radically enhance your capital raising efforts. 


FINTRX delivers an industry-leading suite of family office data and research solutions to the alternative wealth space and private capital markets. Engineered to help asset raising professionals identify and access family office capital in an efficient manner, the FINTRX platform offers high-level family office data and research, built with an intuitive approach.  

To see a glimpse of the technology and how we could help streamline your prospecting processes, please request a demo below:

REQUEST DEMO

For more practical family office insights and best practices, visit our newly renovated 'Resource Library'. 

FINTRX Resource Library CTA

Written by: Renae Hatcher

Renae Hatcher is member of the marketing team at FINTRX - focused on delivering targeted & relevant family office content to our subscribers.

Renae Hatcher
Request trial
additional resources